ZL0590

CAT: 0804-HY-145310-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-145310-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
ZL0590 is a potent, orally active BRD4 BD1-selective inhibitor with an IC50 of 90 nM for human BRD4 BD1. ZL0590 exhibits significant anti-inflammatory activities. ZL0590 can reduce mucosal inflammation in animal models of inflammatory bowel disease and restores tissue architecture. ZL0590 can be used in research on inflammatory diseases such as inflammatory bowel disease[1][2].
CAS Number
[2230496-99-6]
UNSPSC
12352005
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/zl0590.html
Purity
99.86
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=S(N1[C@@H](CCC1)CN2CCOCC2)(C3=CC=C(C=C3)NC(NC4=CC=C(C=C4)C(F)(F)F)=O)=O
Molecular Formula
C23H27F3N4O4S
Molecular Weight
512.55
References & Citations
[1]Liu Z, et al. Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site. J Med Chem. 2022;65 (3) :2388-2408. |[2]Yi Li, et al., DEVELOPMENT OF SMALL MOLECULE EPIGENETIC THERAPEUTICS FOR INFLAMMATORY BOWEL DISEASE, 2021 160 (3) .
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-126428-01ZL0580
HY-112149-01ZL0420
HY-173450ZL0516
HY-112149A-01(E/Z) -ZL0420

Alternative Products

CatalogName
BA4717-1ZL0590

Popular Products